



## AMENDMENT TRANSMITTAL

\$GP 1647

CASE DOCKET NO. 3718-6

IN RE THE APPLICATION OF:

BRENNAN et al.

SERIAL NO: 09/458,579

DATE FILED: December 9, 1999

FOR: "METHODS FOR IDENTIFYING COMPOUNDS USEFUL FOR THE REGULATION OF BODY WEIGHT AND ASSOCIATED CONDITIONS"

ASSISTANT COMMISSIONER FOR PATENTS  
WASHINGTON, D.C. 20231

SIR:

TRANSMITTED HERewith IS AN AMENDMENT IN THE ABOVE-IDENTIFIED APPLICATION

- [X] SMALL ENTITY STATUS OF THIS APPLICATION UNDER 37 CFR 1.9 AND 1.27 HAS BEEN ESTABLISHED BY A VERIFIED STATEMENT PREVIOUSLY SUBMITTED.
- [ ] A VERIFIED STATEMENT TO ESTABLISH SMALL ENTITY STATUS UNDER 37 CFR 1.9 AND 1.27 IS ENCLOSED.
- [ ] NO ADDITIONAL FEE IS REQUIRED.

RECEIVED  
OCT 19 2001  
TECH CENTER 1600/2900

THE FILING FEE HAS BEEN CALCULATED AS SHOWN BELOW:

	(COL. 1) CLAIMS REMAINING AFTER AMENDMENT	(COL. 2) HIGHEST NO. PREVIOUSLY PAID FOR		(COL. 3) PRESENT EXTRA	SMALL ENTITY			LARGE ENTITY	
					RATE	ADDITIONAL FEE		RATE	ADDITIONAL FEE
TOTAL:	*24	-	** 21	3	X \$9 =	\$27.00	OR	X \$18 =	
INDEP:	9	-	*** 7	2	X \$42 =	\$84.00	OR	X \$84 =	
FIRST PRESENTATION OF MULTIPLE DEPENDENT CLAIMS					+ \$140 =		OR	+ \$280 =	
ADDITIONAL FEES					TOTAL:	\$111.00	OR	TOTAL:	

\*IF THE ENTRY IN COL. 1 IS LESS THAN THE ENTRY IN COL. 2, WRITE "0" IN COL. 3.

\*\*IF THE "HIGHEST NUMBER PREVIOUSLY PAID FOR" IN THIS SPACE IS LESS THAN 20, WRITE "20" IN THIS SPACE.

\*\*\*IF THE "HIGHEST NUMBER PREVIOUSLY PAID FOR" IN THIS SPACE IS LESS THAN 3, WRITE "3" IN THIS SPACE.

THE "HIGHEST NUMBER PREVIOUSLY PAID FOR" (TOTAL OR INDEPENDENT) IS THE HIGHEST NUMBER FOUND FROM THE EQUIVALENT BOX IN COL. 1 OF A PRIOR AMENDMENT OR THE NUMBER OF CLAIMS ORIGINALLY FILED.

- [ ] PLEASE CHARGE DEPOSIT ACCOUNT NO. 19-1970 IN THE AMOUNT OF \$\_\_\_\_. A DUPLICATE COPY OF THIS SHEET IS ENCLOSED.
- [X] A CHECK IN THE AMOUNT OF \$ 111 TO COVER THE FEE IS ENCLOSED.
- [X] THE COMMISSIONER IS HEREBY AUTHORIZED TO CHARGE PAYMENT OF THE FOLLOWING FEES ASSOCIATED WITH THIS COMMUNICATION OR CREDIT ANY OVERPAYMENT TO DEPOSIT ACCOUNT NO. 19-1970. A DUPLICATE COPY OF THIS SHEET IS ENCLOSED.
- [X] ANY FILING FEES UNDER 37 CFR 1.16 FOR THE PRESENTATION OF EXTRA CLAIMS.
- [X] ANY PATENT APPLICATION PROCESSING FEES UNDER 37 CFR 1.17.

RESPECTFULLY SUBMITTED,

SHERIDAN ROSS P.C.

  
Angela K. Dallas  
Registration No. 42,460

## CERTIFICATE OF MAILING

I HEREBY CERTIFY THAT THIS CORRESPONDENCE IS  
BEING DEPOSITED WITH THE UNITED STATES POSTAL  
SERVICE AS FIRST CLASS MAIL IN AN ENVELOPE  
ADDRESSED TO THE ASSISTANT COMMISSIONER FOR  
PATENTS, WASHINGTON, DC 20231 ON 10/5/01  
SHERIDAN ROSS P.C.

BY:



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In Re the Application of:

BRENNAN et al.

Serial No.: 09/458,579

Filed: December 9, 1999

Atty. File No.: 3718-6

For: "METHODS FOR IDENTIFYING  
COMPOUNDS USEFUL FOR THE  
REGULATION OF BODY WEIGHT  
AND ASSOCIATED CONDITIONS"

Group Art Unit: 1647

Examiner: Seharaseyon, J.

AMENDMENT AND RESPONSE

CERTIFICATE OF MAILING

I HEREBY CERTIFY THAT THIS CORRESPONDENCE IS  
BEING DEPOSITED WITH THE UNITED STATES POSTAL  
SERVICE AS FIRST CLASS MAIL IN AN ENVELOPE  
ADDRESSED TO THE ASSISTANT COMMISSIONER FOR  
PATENTS, WASHINGTON, DC 20231 ON 10/5/01  
SHERIDAN ROSS P.O.

BY:

Commissioner of Patents  
Washington, D.C. 20231

Dear Sir:

This Amendment and Response is filed in response to an Office Action having a mailing date of July 5, 2001. Enclosed are additional fees for added claims. This response is believed to be timely and therefore, no fees are enclosed other than those for added claims. In the event that fees are due, please debit Deposit Account No. 19-1970.

Please amend and reconsider the above-identified patent application as follows.

IN THE CLAIMS:

Please cancel Claims 10-14, without prejudice to or disclaimer of the subject matter therein.

Please amend Claims 6 and 19, without prejudice to or disclaimer of the subject matter therein.

Please add new Claims 22-29 as set forth below.

6. (Once Amended) A method for identifying compounds that increase body weight by regulating peripheral pathways of energy homeostasis, comprising:

a. contacting a cell which expresses a melanocortin receptor selected from the group consisting of melanocortin 2-receptor (MC2-R) and melanocortin 5-

#134/JPW  
10-20-01  
RECEIVED  
OCT 19 2001  
TECH CENTER 160012900